R. Wang

Hebei Medical University

Papers

1

Total Citations

10

H-Index

1

About

No biography available yet.

Research Focus

Adenocarcinoma1 · 10 citations
Adverse effect1 · 10 citations
Breast cancer1 · 10 citations
Cancer1 · 10 citations
Clinical endpoint1 · 10 citations
Clinical trial1 · 10 citations
Internal medicine1 · 10 citations
Lung cancer1 · 10 citations
Medicine1 · 10 citations
Neoadjuvant therapy1 · 10 citations
Oncology1 · 10 citations
Osimertinib1 · 10 citations

Key Achievements

1
H-Index
1
Papers
10
Total Citations
10
Avg Citations/Paper
🏆 Most Cited Paper
81MO Osimertinib as neoadjuvant therapy in patients with EGFR mutated resectable stage II-IIIB lung adenocarcinoma (NEOS): Updated results
10 citations · 2022
📈 Most Prolific Year: 2022 (1 Papers)
🤝 Key Collaborators: 8
🏛 Institutions: Hebei Medical University

Top Papers

  1. 1
    81MO Osimertinib as neoadjuvant therapy in patients with EGFR mutated resectable stage II-IIIB lung adenocarcinoma (NEOS): Updated results
    10 citations · 2022

Key Collaborators

WJWeiqi Jiao1 shared papersNWNan Wu1 shared papersWFWentao Fang1 shared papersSXS. Xu1 shared papersHMHaitao Ma1 shared papersYYYongbo Yang1 shared papersJWJ. Wang1 shared papersCJChuhl Joo Lyu1 shared papers
Not generated yet